IUdR/BUdR Cell Cycle Labelling - Tabular View

Tracking Information

First Received Date ^ICMJE

July 24, 2002

Last Updated Date

June 23, 2005

Start Date ^ICMJE

October 1991

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00042250 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

IUdR/BUdR Cell Cycle Labelling

Official Title ^ICMJE

Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Brief Summary

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Detailed Description

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study

Condition ^ICMJE

Hematologic Malignancies

Intervention ^ICMJE

Drug: Chemotherapy for hematologic malignancy

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Terminated

Enrollment ^ICMJE

180

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Histologic proof of one of:

AML, ALL, or AUL
MDS or CMML
CML
OR undergoing bone marrow transplantation.

Participants should be:

off therapy for at least two weeks
At least 18 years old or older
Using adequate contraception if of child-bearing capability.

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00042250

Responsible Party

Study ID Numbers ^ICMJE

DM91-102

Study Sponsor ^ICMJE

M.D. Anderson Cancer Center

Collaborators ^ICMJE

Investigators ^ICMJE

Study Chair:

Michael Andreeff, MD, PhD

U. T. M. D. Anderson Cancer Center

Information Provided By

M.D. Anderson Cancer Center

Verification Date

January 2004

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP